Form 8-K - Current report:
SEC Accession No. 0001493152-25-009784
Filing Date
2025-03-11
Accepted
2025-03-11 08:05:25
Documents
17
Period of Report
2025-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43933
2 ex4-1.htm EX-4.1 128180
3 ex4-2.htm EX-4.2 133450
4 ex10-1.htm EX-10.1 201004
5 ex99-1.htm EX-99.1 18601
  Complete submission text file 0001493152-25-009784.txt   811673

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE awh-20250305.xsd EX-101.SCH 3012
7 XBRL LABEL FILE awh-20250305_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE awh-20250305_pre.xml EX-101.PRE 24164
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3825
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 25725904
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)